Bellicum Pharmaceuticals Files For IPO

Houston-based Bellicum Pharmaceuticals has filed for an IPO, saying in documents filed with the SEC that it is looking to raised up to $115M on the NASDAQ Global Market as BLCM. The IPO is being underwritten by Jeffries, Citigroup, and Piper Jaffray. Bellicum is venture backed by Baker Biotech Capital, Mcguyer Investments Ltd., Remeditex Ventures, AVG Ventures, RA CApital Healthcare, along with others. Bellicum is a clinical stage biopharmaceutical company which is focused on treatments for cancer; the company's lead compound, BPX-501, is in Phase 1 and 2 trials.